虚拟筛选
药品
抗病毒药物
药物发现
冠状病毒
英迪纳维
药理学
药物重新定位
2019年冠状病毒病(COVID-19)
可药性
计算生物学
病毒学
医学
生物
传染病(医学专业)
生物信息学
病毒载量
病毒
疾病
生物化学
抗逆转录病毒疗法
基因
内科学
作者
Zhenming Jin,Xiaoyu Du,Yechun Xu,Yong‐Qiang Deng,Meiqin Liu,Yao Zhao,Bing Zhang,Xiaofeng Li,Leike Zhang,Chao Peng,Yinkai Duan,Jing Yu,Lin Wang,Kailin Yang,Fengjiang Liu,Ren-Di Jiang,Xing‐Lou Yang,Tian You,Xiaoce Liu,Xiuna Yang
出处
期刊:Nature
[Nature Portfolio]
日期:2020-04-09
卷期号:582 (7811): 289-293
被引量:4497
标识
DOI:10.1038/s41586-020-2223-y
摘要
A new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the aetiological agent responsible for the 2019-2020 viral pneumonia outbreak of coronavirus disease 2019 (COVID-19)1-4. Currently, there are no targeted therapeutic agents for the treatment of this disease, and effective treatment options remain very limited. Here we describe the results of a programme that aimed to rapidly discover lead compounds for clinical use, by combining structure-assisted drug design, virtual drug screening and high-throughput screening. This programme focused on identifying drug leads that target main protease (Mpro) of SARS-CoV-2: Mpro is a key enzyme of coronaviruses and has a pivotal role in mediating viral replication and transcription, making it an attractive drug target for SARS-CoV-25,6. We identified a mechanism-based inhibitor (N3) by computer-aided drug design, and then determined the crystal structure of Mpro of SARS-CoV-2 in complex with this compound. Through a combination of structure-based virtual and high-throughput screening, we assayed more than 10,000 compounds-including approved drugs, drug candidates in clinical trials and other pharmacologically active compounds-as inhibitors of Mpro. Six of these compounds inhibited Mpro, showing half-maximal inhibitory concentration values that ranged from 0.67 to 21.4 μM. One of these compounds (ebselen) also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of our screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.
科研通智能强力驱动
Strongly Powered by AbleSci AI